Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Sintetica Limited, 30<sup>th</sup> Floor, 40 Bank Street, Canary Wharf, London, E14 5NR, United Kingdom
Prilotekal 20mg/ml solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless solution. The pH is between 5.0 and 6.0. The solution is hyperbaric with osmolality comprised between 490 and 540 mOsm/kg. |
1 ml of solution for injection contains 20 mg of prilocaine hydrochloride (equivalent to 2%).
1 ampoule with 5 ml solution, contains 100 mg of prilocaine hydrochloride.
Excipients: 0.0086 mg sodium per 1 ml.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Prilocaine |
Prilocaine is a toluidine derivative and intermediate-acting amino amide with local anesthetic property. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns. |
| List of Excipients |
|---|
|
Glucose anhydrous or glucose monohydrate |
Type I clear colourless glass ampoule.
Box of 10 ampoules each containing 5 ml of solution for injection.
Sintetica Limited, 30th Floor, 40 Bank Street, Canary Wharf, London, E14 5NR, United Kingdom
PL 46926/0002
27/01/2017
| Drug | Countries | |
|---|---|---|
| PRILOTEKAL | Netherlands, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
